GETTING STARTED

  • Prior to initiating AUGTYRO, discontinue strong and moderate CYP3A inhibitors for 3 to 5 elimination half-lives of the CYP3A inhibitor1

Recommended testing for initiation and follow-up1

Test Prior to Initiation Monitoring
Liver function tests including bilirubin Checkmark Every 2 weeks for first month; monthly thereafter and/or as clinically indicated1
Uric acid level Checkmark Periodic monitoring during treatment1
Serum CPK levels N/A Every 2 weeks for first month; periodic monitoring as clinically indicated thereafter1
Interstitial lung disease/pneumonitis N/A Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis1

RECOMMENDED DOSING

Recommended dosing of AUGTYRO1

RECOMMENDED ORAL DOSE OF AUGTYRO1* Days 1-14 Day 15 Onward
160 mg QD
(4x 40-mg capsules, or a single 160-mg capsule, once daily)		 160 mg BID
(4x 40-mg capsules, or a single 160-mg capsule, twice daily)
* Until disease progression or unacceptable toxicity.
Steaming pot

AUGTYRO can be taken with or without food1†

Clock

Capsules should be swallowed whole at approximately the same time every day as prescribed1

Crossed out medicine capsule being emptied

Contents of the capsule should not be opened, crushed, chewed, or dissolved1

Patient vomiting at toilet

If a dose is missed or if a patient vomits at any time after taking a dose, instruct patients to skip the dose and resume at the regularly scheduled time. Two doses should not be taken at the same time1

† Advise patients not to drink grapefruit juice or eat grapefruit while taking AUGTYRO.1

DOSE MODIFICATIONS

Recommended dosage reductions with AUGTYRO1

Adjustable dosing allows for dose modification if needed for adverse reactions‡

Recommended Dosage Reductions for Adverse Reactions1
Dose Dose Reduction
First Second
160 mg Once Daily 120 mg Once Daily 80 mg Once Daily
160 mg Twice Daily 120 mg Twice Daily 80 mg Twice Daily
Light bulb

Central nervous system effects1

  • If intolerable Grade 2, withhold AUGTYRO until ≤Grade 1 or baseline, then resume at same or reduced dose, as clinically appropriate
  • If Grade 3, withhold AUGTYRO until ≤Grade 1 or baseline, then resume at reduced dose
  • If Grade 4, permanently discontinue AUGTYRO

ILD/pneumonitis1

  • For any grade, withhold AUGTYRO if ILD/pneumonitis is suspected and permanently discontinue if confirmed

Hepatotoxicity1

  • If Grade 3, withhold AUGTYRO until ≤Grade 1 or baseline. Resume at same dose if resolution occurs within 4 weeks, or at reduced dose for recurrent Grade 3 events that resolve within 4 weeks
  • If Grade 4, withhold AUGTYRO until ≤Grade 1 or baseline. Resume at reduced dose if resolution occurs within 4 weeks. Permanently discontinue if AR does not resolve within 4 weeks or if it recurs
  • If ALT or AST >3 times the ULN with concurrent total bilirubin >1.5 times ULN (in absence of cholestasis or hemolysis), permanently discontinue AUGTYRO

CPK Elevation1

  • If CPK elevation >5 times ULN, withhold AUGTYRO until baseline or ≤2.5 times ULN, then resume at same dose
  • If CPK elevation >10 times ULN or second occurrence of CPK elevation of >5 times ULN, withhold AUGTYRO until baseline or ≤2.5 times ULN, then resume at reduced dose

Hyperuricemia1

  • If Grade 3 or 4, withhold AUGTYRO until improvement of signs or symptoms, then resume AUGTYRO at same or reduced dose

Other clinically relevant adverse events1

  • If intolerable Grade 2, Grade 3, or Grade 4 AR, withhold AUGTYRO until ≤Grade 1 or baseline, then resume at same or reduced dose if resolution occurs within 4 weeks. Permanently discontinue if AR does not resolve within 4 weeks, or if recurrent Grade 4
‡ Graded per CTCAE v4.03.

DISCOVER THE EFFICACY DATA →

SEE THE SAFETY PROFILE →

AUGTYRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

ALT=alanine transaminase; AR=adverse reaction; AST=aspartate transaminase; CPK=creatinine phosphokinase; CTCAE=Common Terminology Criteria for Adverse Events; ILD=interstitial lung disease; ULN=upper limit of normal.

Reference:
1. AUGTYRO [package insert]. Princeton, NJ. Bristol-Myers Squibb Company. 


IMPORTANT SAFETY INFORMATION

SUMMARY OF WARNINGS AND PRECAUTIONS

AUGTYRO was assessed in 426 patients with ROS1+ NSCLC and other solid tumors in the TRIDENT-1 pivotal study and is associated with the following warnings and precautions: central nervous system (CNS) adverse reactions, interstitial lung disease (ILD)/pneumonitis, hepatotoxicity, myalgia with creatine phosphokinase (CPK) elevation, hyperuricemia, skeletal fractures, and embryo-fetal toxicity.

INDICATION

AUGTYRO® (repotrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Central Nervous System Adverse Reactions

  • Among the 426 patients who received AUGTYRO in Study TRIDENT-1, a broad spectrum of central nervous system (CNS) adverse reactions including dizziness, ataxia, and cognitive disorders occurred in 77% of patients with Grade 3 or 4 events occurring in 4.5%.
  • Dizziness, including vertigo, occurred in 65%; Grade 3 dizziness occurred in 2.8% of patients.
  • Ataxia, including gait disturbance and balance disorder, occurred in 28% of patients; Grade 3 ataxia occurred in 0.5%. 
  • Cognitive impairment, including memory impairment and disturbance in attention, occurred in 25% of patients. Cognitive impairment included memory impairment (15%), disturbance in attention (12%), and confusional state (2%); Grade 3 cognitive impairment occurred in 0.9% of patients.
  • Mood disorders occurred in 6% of patients. Mood disorders occurring in >1% of patients included anxiety (2.6%); Grade 4 mood disorders (mania) occurred in 0.2% of patients.
  • Sleep disorders including insomnia and hypersomnia occurred in 18% of patients. Sleep disorders observed in >1% of patients were somnolence (9%), insomnia (6%) and hypersomnia (1.6%). 
  • The incidences of CNS adverse reactions reported were similar in patients with and without CNS metastases.
  • Advise patients not to drive or use machines if they are experiencing CNS adverse reactions. Withhold and then resume at same or reduced dose upon improvement, or permanently discontinue AUGTYRO based on severity.

Interstitial Lung Disease (ILD)/Pneumonitis

  • ILD/pneumonitis (pneumonitis [2.8%] and ILD [0.2%]) occurred in 3.1%; Grade 3 ILD/pneumonitis occurred in 1.2%.
  • Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Immediately withhold AUGTYRO in patients with suspected ILD/pneumonitis and permanently discontinue AUGTYRO if ILD/pneumonitis is confirmed.

Hepatotoxicity

  • Increased alanine transaminase (ALT) occurred in 38%, increased aspartate aminotransferase (AST) occurred in 41%, including Grade 3 or 4 increased ALT in 3.3% and increased AST in 2.9%.
  • Monitor liver function tests, including ALT, AST and bilirubin, every 2 weeks during the first month of treatment, then monthly thereafter and then as clinically indicated. Withhold and then resume at same or reduced dose upon improvement or permanently discontinue AUGTYRO based on the severity.

Myalgia with Creatine Phosphokinase (CPK) Elevation

  • AUGTYRO can cause myalgia with or without creatine phosphokinase (CPK) elevation. Myalgia occurred in 13% of patients, with Grade 3 in 0.7%. Concurrent increased CPK within a 7-day window was observed in 3.7% of patients.
  • Advise patients to report any unexplained muscle pain, tenderness, or weakness. Monitor serum CPK levels during AUGTYRO treatment and monitor CPK levels every 2 weeks during the first month of treatment and as needed in patients reporting unexplained muscle pain, tenderness, or weakness. Initiate supportive care as clinically indicated. Based on severity, withhold and then resume AUGTYRO at same or reduced dose upon improvement.

Hyperuricemia

  • 21 patients (5%) experienced hyperuricemia reported as an adverse reaction, 0.7% experienced Grade 3 or 4 hyperuricemia. One patient without pre-existing gout required urate-lowering medication.
  • Monitor serum uric acid levels prior to initiating AUGTYRO and periodically during treatment. Initiate treatment with urate-lowering medications as clinically indicated. Withhold and then resume at same or reduced dose upon improvement, or permanently discontinue AUGTYRO based on severity.

Skeletal Fractures

  • Fractures occurred in 2.3% of patients and involved the ribs (0.5%), feet (0.5%), spine (0.2%), acetabulum (0.2%), sternum (0.2%), and ankles (0.2%). Some fractures occurred at sites of disease and prior radiation therapy.
  • Of 26 evaluable patients in an ongoing open-label study in pediatric patients, fractures occurred in one 12-year-old patient (ankle/foot) and one 10-year-old patient (stress fracture). AUGTYRO is not approved for use in pediatric patients less than 12 years of age.
  • Promptly evaluate patients with signs or symptoms (e.g., pain, changes in mobility, deformity) of fractures. There are no data on the effects of AUGTYRO on healing of known fractures and risk of future fractures.

Embryo-Fetal Toxicity

  • Based on literature reports in humans with congenital mutations leading to changes in tropomyosin receptor tyrosine kinase (TRK) signaling, findings from animal studies, and its mechanism of action, AUGTYRO can cause fetal harm when administered to a pregnant woman.
  • Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with AUGTYRO and for 2 months following the last dose, since AUGTYRO can render some hormonal contraceptives ineffective.
  • Advise male patients with female partners of reproductive potential to use effective contraception during treatment with AUGTYRO and for 4 months after the last dose.

Adverse Reactions

  • The safety of AUGTYRO was evaluated in 426 patients in TRIDENT-1. The most common adverse reactions (≥20%) were dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, and nausea.

Drug Interactions

Effects of Other Drugs on AUGTYRO

  • Avoid concomitant use with P-gp inhibitors, strong or moderate CYP3A inducers, and strong or moderate CYP3A inhibitors. Discontinue CYP3A inhibitors for 3 to 5 elimination half-lives of the CYP3A inhibitor prior to initiating AUGTYRO.

Effects of AUGTYRO on other Drugs

Certain CYP3A4 Substrates

  • Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP3A substrates, where minimal concentration changes can cause reduced efficacy. If concomitant use is unavoidable, increase the CYP3A4 substrate dosage in accordance with approved product labeling.
  • Repotrectinib is a CYP3A4 inducer. Concomitant use of repotrectinib decreases the concentration of CYP3A4 substrates, which can reduce the efficacy of these substrates.

Contraceptives

  • Repotrectinib can decrease progestin or estrogen exposure to an extent that could reduce the effectiveness of hormonal contraceptives.
  • Avoid concomitant use of AUGTYRO with hormonal contraceptives. Advise females of childbearing potential to use an effective nonhormonal contraceptive.

Please see Full U.S. Full Prescribing Information for AUGTYRO.

3600-US-2400347   04/25

Bristol Myers Squibb logo

Legal Notice      Privacy Policy      Your Privacy Choices Privacy Link      Site Map     

This site is intended for U.S. Healthcare Professionals only.
© 2025 Turning Point Therapeutics, Inc., a Bristol Myers Squibb company.
AUGTYRO® and the related logo are trademarks of Turning Point Therapeutics, Inc.

3600-US-2400348   04/25